Fate Therapeutics, Inc.

NASDAQ:FATE

Biotechnology

Healthcare
$1.05 -0.00%

-$0.00 today

Market cap
$122.39M
Beta
2.52
P/E (TTM)
-1.8
EPS (TTM)
-$1.08
52W Low $0.91High $2.88

Volume 1.87M

Average 2.92M

FATE Other Non-Cash Items

Other non-cash adjustments that reconcile net income to operating cash flow.

Fate Therapeutics, Inc.NASDAQ: FATE

Other Non-Cash Items · Q1 FY2026 · quarter ended Mar 2026

Other non-cash items turns positive

Q1 FY2026 other non-cash items was $280K, compared with -$1.53M a year earlier. Trailing-twelve-month other non-cash items was -$2.04M. Over 3 fiscal years it compounded at -78.3% a year.

Context

  • Other non-cash items amounted to 3.7% of revenue in FY2025, down 32.1 pp from a year earlier.
  • Other non-cash items increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly other non-cash items holds near $280K or moves back toward the trailing-twelve-month quarterly average of -$511K.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$280K+147.8% QoQ
Last fiscal yearDec 2025
-$247K-105.1% YoY
LTMMar 2026
-$2.04M-139.9% YoY
Other Non-Cash Items past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+118.3%——
1 year-105.1%——
3-year CAGR-78.3%——
5-year CAGR——
10-year CAGR——

Other Non-Cash Items history

USD · from the cash flow

Latest · FY2025
(247K) USD
Year-over-year change
-105.1%

Other Non-Cash Items vs competitors

How FATE compares with its peers on the latest reported figures

  • Peers report in different currencies, so other non-cash items is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -139.9% is the lowest of 10, against a peer median of +119.5%.
  • Other non-cash items amounts to 32.4% of revenue for FATE, versus a peer median of 4.9%.
FATE Competitors
Other Non-Cash Items for FATE and competitors
Company Period LTM YoY 3-year CAGR% of revenue
VORVor Biopharma Inc.LTM Mar 2026$707.94M USD+14741.6%+333.0%—
MOLNMolecular Partners AGLTM Mar 2026CHF 4.3M CHF+257.9%——
PEPGPepGen Inc.LTM Mar 2026$2.6M USD+225.7%——
FATEFate Therapeutics, Inc.LTM Mar 2026$2.04M USD-139.9%-78.3%32.4%
INOInovio Pharmaceuticals, Inc.LTM Mar 2026$1.5M USD+119.5%——
CRBPCorbus Pharmaceuticals Holdings, Inc.LTM Mar 2026$1.13M USD-30.3%——
ALECAlector, Inc.LTM Mar 2026$879K USD-90.8%—4.8%
PRLDPrelude Therapeutics IncorporatedLTM Mar 2026$832K USD+121.2%-29.1%5.0%
ABOSAcumen Pharmaceuticals, Inc.LTM Mar 2026$572K USD+113.0%+55.0%—
NKTXNkarta, Inc.LTM Mar 2026$561K USD-88.1%-9.8%—
Peer median (excluding FATE) —+119.5%+22.6%4.9%

Competitors are the stored peer set for FATE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(212.15M)(281.72M)(160.93M)(186.26M)(136.32M)
Depreciation & Amortization5.85M13.76M18.28M18.96M9.3M
Deferred Income Tax00000
Stock-Based Compensation54.36M78.73M43.46M41.5M24.92M
Change in Working Capital2.1M(34.71M)19.18M(1.96M)(3.74M)
Accounts Receivables(3.16M)(29.8M)36.65M(1.11M)2.62M
Inventory00000
Accounts Payables014.25M(28.94M)(1.66M)(9.03M)
Other Working Capital5.26M(19.16M)11.47M816K2.66M
Other Non-Cash Items(13.03M)(24.27M)(52.26M)4.89M(247K)
Operating Cash Flow(162.87M)(248.21M)(132.26M)(122.87M)(106.08M)
Capital Expenditures(50.7M)(35.57M)(6.15M)(730K)(5.95M)
Acquisitions (Net)0000362K
Purchases of Investments(968.16M)(404.8M)(358.81M)(317.75M)(195.14M)
Sales of Investments694.84M607.11M477.63M330.7M311.9M
Other Investing Activities00000
Investing Cash Flow(324.02M)166.75M112.67M12.22M111.17M
Debt Repayment00000
Common Stock Issued411.74M9.21M85K94.82M0
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities41.39M005.07M5.49M
Financing Cash Flow453.13M9.21M85K99.89M5.49M
Effect of Forex Changes0050K4.95M0
Net Change in Cash(33.76M)(72.25M)(19.46M)(5.81M)10.57M
Free Cash Flow(213.57M)(283.77M)(138.42M)(123.6M)(112.04M)

Fate Therapeutics, Inc.

NASDAQ:FATE

Intrinsic Alpha fair value

Locked

Current Price

$1.05

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.